Abstract：【Objective】 To investigate the pulmonary function, inflammatory factors and clinical outcomes of children with refractory mycoplasma pneumoniae pneumonia (RMPP) and Mycoplasma pneumoniae pneumonia (MPP). 【Methods】A total of 110 children with MPP treated in our hospital from January 2019 to January 2022 were selected, of which 48 children with RMPP were included in the RMPP group and 62 children with common MPP were included in the MPP group. Levels of the pulmonary function indexes in acute stage and convalescent stage in terms of [first second forced expiratory volume (FEV1), forced vital capacity (FVC), FEV1/FVC], serum inflammatory factors [interleukin-2 (IL-2), interleukin-6(IL-6), tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ)] and abnormal lung function were compared between the two groups.【Results】FEV1 and FVC in the recovery stage were higher than those in the acute stage (P<0.05), but there was no significant difference in FEV1/FVC in the acute stage and the recovery stage between the two groups (P>0.05). The FEV1 and FVC of the RMPP group in acute stage and recovery stage were lower than those of the MPP group (P<0.05). Serum levels of IL-2, IL-6, TNF-α and INF-γ in the recovery stage were lower than those in the acute stage (P<0.05). The serum levels of IL-2, IL-6, TNF-α and INF-γ in RMPP group were higher than those in the MPP group (P<0.05). There was no significant difference in the incidence of abnormal lung function between the two groups (P>0.05). The proportion of children with normal lung function in the RMPP group was lower than that in the MPP group, and the proportion of children with restrictive ventilation dysfunction was higher than that in the MPP group (P<0.05). 【Conclusion】Compared with children with MPP, children with RMPP have more severe lung function injury and inflammation. From the acute stage to the convalescent stage, both children with RMPP and MPP have improved lung function and reduced inflammation. However, children with RMPP have poor recovery and clinical outcomes, and a higher proportion of restricted ventilation dysfunction in convalescent stage.
[1] DESAI S, HALL M, LIPSETT S C, et al. Mycoplasma pneumoniae testing and treatment among children with community-acquired pneumonia[J].Hosp Pediatr,2021,11(7):760-763.
[2] CHEN Y C, HSU W Y, CHANG T H. Macrolide-resistant mycoplasma pneumoniae infections in pediatric community-acquired pneumonia[J].Emerg Infect Dis,2020,26(7):1382-1391.
[3] 管峥,霍洁,袁晶,等. 血清乳酸脱氢酶联合白细胞介素18对儿童难治性肺炎支原体肺炎的预测作用[J].实用医学杂志,2020,36(20):2848-2851.
[4] 中华医学会儿科学分会呼吸学组,《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J].中华实用儿科临床杂志,2015,30(17):1304-1308.
[5] KUTTY P K, JAIN S, TAYLOR T H, et al. Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia[J].Clin Infect Dis,2019,68(1):5-12.
[6] SAUTEUR P M M, THEILER M, BUETTCHER M, et al.Frequency and clinical presentation of mucocutaneous disease due to mycoplasma pneumoniae infection in children with community-acquired pneumonia[J].JAMA Dermatol,2020,156(2):144-150.
[7] 黄殷,潘志伟,阳池娇,等. 气管肺泡灌洗联合免疫球蛋白对难治性肺炎支原体肺炎患儿肺功能及血液感染指标的影响[J].中国妇幼保健,2021,36(20):4738-4741.
[8] 吴卫照,刘东成.支气管镜肺泡灌洗治疗幼儿重症肺炎支原体肺炎的疗效观察及肺功能的变化特点[J].实用医学杂志,2019,35(1):132-135.
[9] 郭艳霞,冯艳芳,沈丹华,等. 儿童普通及难治性支原体肺炎维生素A水平及免疫功能的临床分析[J].广西医科大学学报,2019,36(1):23-26.
[10] 李佳潞,杨俊,朱晓萍,等. 肺炎支原体肺炎合并喘息患儿血清25(OH)D3水平与肺功能的相关性及其影响因素分析[J].现代生物医学进展,2021,21(11):2143-2147.
[11] 彭巍巍,周红超,孙瑞.难治性肺炎支原体肺炎患儿临床特点、高分辨CT影像特点及肺功能变化的临床分析[J].中国CT和MRI杂志,2019,17(12):49-51.
[12] 常春霞.难治性肺炎支原体肺炎患儿实验室指标及临床特点分析[J].中国妇幼保健,2019,34(5):1085-1088.
[13] 秦文卿,张慧,陈刚,等. 难治性肺炎支原体肺炎患儿血清炎性细胞因子变化的临床意义及其危险因素分析[J].现代生物医学进展,2020,20(17):3301-3304.
[14] 周晓飞,过毅. 儿童难治性肺炎支原体肺炎血清中IL-6、IL-10及免疫功能的变化及临床意义[J].中国优生与遗传杂志,2019,27(10):1270-1272.
2025, Vol. 42 
